Updated
Updated · Scientific American · May 19
Scientists Test Drugs to Cut GLP-1 Muscle Loss as 25% to 40% of Weight Shed Is Lean Mass
Updated
Updated · Scientific American · May 19

Scientists Test Drugs to Cut GLP-1 Muscle Loss as 25% to 40% of Weight Shed Is Lean Mass

7 articles · Updated · Scientific American · May 19
  • Eli Lilly’s phase 2 trial paired bimagrumab with semaglutide and delivered 22% weight loss over 72 weeks, with 92% of pounds lost coming from fat versus 76% on semaglutide alone.
  • That push reflects a growing concern that GLP-1 drugs such as Wegovy, Ozempic and Zepbound can strip muscle alongside fat; studies estimate users may lose muscle mass equivalent to 20 years of age-related decline within a few years.
  • Older adults are a key focus because muscle naturally falls about 30% between the 20s and 80s, and added loss can raise risks of falls, fractures, weaker mobility and metabolic decline.
  • Researchers are also testing SARMs, but safety remains unclear, and bimagrumab’s earlier studies increased muscle without clear gains in walking speed or endurance.
  • Until larger human trials prove these add-on drugs safe and effective, experts still point to resistance training and roughly 1.2 to 1.6 grams of protein per kilogram a day as the best-supported protection.
Beyond Ozempic: Will new drugs let you lose only fat and even gain muscle?
New studies say Ozempic's muscle loss is modest. Is the panic overblown?

Maximizing Fat Loss, Preserving Muscle: BELIEVE Trial’s 22% Weight Loss Breakthrough With Bimagrumab and Semaglutide

Overview

The BELIEVE trial marks a major breakthrough in obesity treatment by combining bimagrumab and semaglutide. Published in 2026, this phase 2 study showed that participants lost an average of 22.1% of their body weight over 72 weeks. Impressively, 92% of this weight loss came from fat, while lean muscle loss was minimized to just 2.9%. This significant preservation of muscle mass sets the combination therapy apart from existing treatments, which often lead to unwanted muscle loss. The BELIEVE trial’s results highlight a new direction in weight management, focusing on healthier, higher-quality weight loss.

...